Table 3 The most frequently mutated genes in each molecular subtype [17,18]
From: Molecular characterization and targeted therapeutic approaches in breast cancer
Luminal A | Luminal B | HER2-enriched | Basal-like | ||||
|---|---|---|---|---|---|---|---|
PIK3CA | 45% | PIK3CA | 29% | TP53 | 72% | TP53 | 80% |
MAP3K1 | 13% | TP53 | 29% | PIK3CA | 39% | TTN | 19% |
GATA3 | 13% | GATA3 | 13% | MUC16 | 14% | USH2A | 11% |
TP53 | 12% | TTN | 12% | LRP1 | 8% | FLG | 7% |
CDH1 | 9% | RYR2 | 7% | ERBB3 | 8% | MUC16 | 7% |
TTN | 9% | RELN | 5% | DNAH11 | 8% | PIK3CA | 7% |
MLL3 | 7% | FAT3 | 5% | LRP2 | 8% | MUC17 | 6% |
MAP2K4 | 6% | MLL3 | 5% | TTN | 8% | DNAH7 | 5% |
NCOR1 | 5% | MUC16 | 5% | ATP1A4 | 7% | FAT3 | 5% |
AKT1 | 4% | KCNB2 | 4% | KIAA1109 | 7% | SYNE1 | 5% |
PTEN | 4% | MAP3K1 | 4% | CACNA1E | 7% | DST | 5% |